In the treatment of BPH, while both bipolar-transurethral resection of the prostate (B-TURP) and monopolar-TURP (M-TURP) have similar clinical efficacy, B-TURP is associated with fewer adverse events, according to a recent systematic review of the two modalities.
A minimally invasive implant procedure led to a 50% improvement in lower urinary tract symptoms due to BPH, which was maintained for a year, results of a randomized trial showed.
Urology Times is pleased to announce that the publication’s “Coding and Reimbursement” column has been recognized for editorial excellence by the American Society of Business Publication Editors.
Major organizations representing urology are livid at the conclusions of a new report by the U.S. Government Accountability Office, which basically accuses urology practices with in-office intensity-modulated radiation therapy facilities of ripping off Medicare.
If the urologist shortage reaches a critical stage in the United States as many predict, the United Kingdom may offer a glimpse of what the future holds. Urologists in that country rely heavily on nurse practitioners to shoulder the workload, including performing the UK’s most commonly performed urologic procedure, flexible cystoscopy.
Provision of intensity-modulated radiation therapy services performed by self-referring groups “increased rapidly” between 2006 and 2010 while the rate declined for non-self-referring groups, according to a report from the Government Accountability Office.
A group of scientists that includes a urologist is proposing a major update of the way the U.S. approaches diseases now classified as “cancer,” including eliminating that term from tumors considered indolent.
Men who receive decision aids about prostate cancer screening appear to have significantly increased knowledge about screening and less conflict about what to do, but the decision aids show little impact on their decision whether or not to be screened.
Urologist Datta G. Wagle, MD, is one of six new officers elected to the Federation of State Medical Boards House of Delegates.
The urology work force shortage has created a demand for non-physician providers such as nurse practitioners and physician assistants, but the scope of what these allied health professionals can do remains a matter of debate.
New Urology Times blogger Kevin Wayne, PA-C charts his path to becoming a urology physician assistant.
An analysis of data from three studies that involved a total of more than 240,000 participants found that a self-reported history of kidney stones was associated with a statistically significant increased risk of coronary heart disease among women.
Men who are diagnosed with azoospermia are more prone to developing cancer than the general population, according to a recent study.
There is little doubt that the federal government will continue to play an important role subsidizing the training of physicians. However, given the immediate medical education and work force crisis, states will likely be the source of temporary and long-term solutions.
Researchers have identified a genetic mutation that causes congenital malformations of the kidney and urinary tract, the most common cause of kidney failure in children.
Drugs and devices in the pipeline from Targacept, Inc., Cubist, OncoGenex Pharmaceuticals, Inc., Apricus Biosciences, and Nymox Pharmaceutical Corp.
New products and services from GenomeDx Biosciences, the Coding Institute, Astellas Pharma US, Greenbranch Publishing, the National Association for Continence, Perrigo Co., the Bladder Cancer Advocacy Network, and the Brewer Co.
An effort in Sweden aimed at reducing inappropriate use of imaging to stage incident prostate cancer appears to be succeeding, and similar programs may help cut inappropriate imaging in the United States, researchers say.
In this interview, Dr. H. Ballentine Carter clarifies some misconceptions about the AUA PSA guideline and explains how it will benefit patients.
The rate of therapy for localized prostate cancer does not rise in markets with higher penetration of robotic surgical technology and intensity-modulated radiation therapy, according to a study presented at the American Society of Clinical Oncology annual meeting in Chicago.
Repeat injections of onabotulinumtoxinA (Botox) continue to be a safe and effective treatment for urinary incontinence due to neurogenic detrusor overactivity, according to interim results from a long-term extension study of phase III pivotal trials.
Data from a pivotal phase III trial of the radiotherapeutic agent radium Ra 223 dichloride (Xofigo) in castration-resistant prostate cancer patients have been published in the New England Journal of Medicine (2013; 369:213-23).
A greater percentage of men who had an incomplete response to as-needed phosphodiesterase type-5 inhibitor treatment returned to normal erectile function when given tadalafil (Cialis) once daily, compared to placebo, researchers reported.
Colpocleisis is a safe, minimally invasive procedure for treating pelvic organ prolapse in older women, according to the findings of a retrospective study reported by female pelvic medicine surgeons from Loyola University Medical Center, Maywood, IL.
While some urologists interviewed by Urology Times say they keep up on clinical trials and offer them patients, one says that his rural location makes participating in trials difficult both for himself and his patients.
Use of androgen deprivation therapy was associated with a significantly increased risk of acute kidney injury, with variations observed with certain types of ADT, according to a recent study.
Self-referred anatomic pathology services have increased at a faster rate than non-self-referred services, according to a recent report from the Government Accountability Office that quickly drew praise from the College of American Pathologists and criticism from the AUA.
Analyses of data from men in the intervention (screening) arm of the Prostate, Lung, Colorectal, and Ovary (PLCO) study show that prostatic biopsy is not associated with an increased risk of early mortality.
Some men with low-risk prostate cancer who are being managed by active surveillance can have their PSA levels measured every 6 months instead of every 3 months, researchers reported at the American Society of Clinical Oncology annual meeting in Chicago.
In men with diabetes who are diagnosed with prostate cancer, use of metformin reduces both cancer-specific and all-cause mortality, and the treatment benefits increase with increasing cumulative duration of exposure to the drug, according to the results of a retrospective study presented at the American Society of Clinical Oncology annual meeting in Chicago.